BRÈVE

sur Mainz BioMed N.V.

Mainz Biomed Hosts Webinar on Colorectal Cancer Early Detection

Mainz Biomed N.V., in partnership with Ganzimmun, is set to conduct a webinar titled "Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options" on March 20, 2024. This educational event, part of Colorectal Cancer Awareness Month, aims to introduce new laboratory diagnostic methods for colorectal cancer to healthcare professionals. It highlights the importance of genetic markers and advancements in screening technologies, promising a more precise risk assessment and early detection capabilities. Attendees will have the opportunity to earn continuing education credits.

The webinar, offered in German, features Senior Consultant Medical Sciences Jürgen Fuhrländer as the speaker. It targets pharmacists, physicians, and healthcare professionals, providing insights into cutting-edge diagnostic techniques. The session is scheduled from 07:00 PM to 08:15 PM (CET) and is accessible online at no cost. For registration details, interested parties are advised to visit Mainz Biomed's official website or the Ganzimmun platform.

Mainz Biomed underscores the critical role of early detection in improving colorectal cancer outcomes. Their flagship product, ColoAlert®, exemplifies their commitment to advancing non-invasive, accurate cancer screening technologies. The company also emphasizes the potential market opportunity in the US, contingent upon achieving regulatory approval.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Mainz BioMed N.V.